Vanguard Group’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Vanguard Group’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,039,148	Closed	-$397K	–	4630
2022 Q2	$397K	Buy	1,039,148 +864,648	+496%	+$605K	﹤0.01%	4342
2022 Q1	$260K	Buy	174,500 +7,900	+5%	+$10K	﹤0.01%	4499
2021 Q4	$405K	Buy	+166,600	New	+$723K	﹤0.01%	4465

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group's CRXT Position: Q3 2022 in Review

Vanguard Group sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 1,039,148 shares — an estimated $397K sold.

Vanguard Group first reported a position in CRXT in Q4 2021 and held it in 3 quarters. The position peaked at $405K in Q4 2021. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Vanguard Group reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Vanguard Group sold 1,039,148 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $397K.
Vanguard Group first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
Vanguard Group's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $405K in Q4 2021.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.